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Abstract
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed.
Compelling evidence indicates that the immune response against ovarian cancer may play an important role in
controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and
tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for
the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission
of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the
development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunothera-
peutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat
shock protein-peptide complex for the treatment of advanced ovarian cancer.
Introduction
Ovarian cancer occurs with a lifetime incidence in
approximately 1 in 58 women and it is the fifth leading
cause of cancer death in women and is the leading
cause of death among gynecologic cancers. It is esti-
mated that approximately 21,550 new cases of ovarian
cancer were diagnosed in 2009 in the United States with
14,600 deaths[1]. Sixty-seven percent of patients are
d i a g n o s e da ts t a g e sI I Ia n dI V ,w i t hr e s u l t a n tl o wr e l a -
tive-survival rates[1] despite, in many cases, apparently
optimal surgery followed by the most effective combina-
tion chemotherapies available to date. Therefore, there
is a compelling need for innovative and effective
therapies.
Malignant tumors have been shown to be immuno-
genic in some cancer sites, including ovarian cancer.
Some of the strongest evidence linking anti-tumor
immunity and cancer have been made in ovarian cancer
[2-5]. Understanding how the immune response is acti-
vated in ovarian cancer is a prerequisite for designing
clinically meaningful immunologic strategies against this
disease. Over the last two decades, there have been
numerous clinical trials in ovarian cancer using immu-
nologic modalities[6]. Results have been at best mixed,
which demonstrates the need for a thoughtful and
integrative approach to examine the role of immu-
notherapy in this disease. In this article, we will exam-
ine several key issues in this rapidly evolving area,
highlighting the opportunities and challenges. We hope
that our work will provide an overview and contribute
to discovery the most effective immunotherapy of ovar-
ian cancer.
Historical Perspective: Is Cancer Immunogenic?
Immunogenicity is the ability of antigens to elicit an
immune response. It is well known that traditional vac-
cines can be very powerful in the prevention of infec-
tious diseases such as smallpox. The early vaccines
against smallpox, originating in China, were inspired by
the concept of variolation. The term vaccine (adopted
from the Latin vaccin-us,f r o mvacca cow) derives from
Edward Jenner’s use of cow pox particulate, which was
found to provide protection against smallpox when it
was administered to humans around 1796. Nearly 100
years ago, Paul Ehrlich proposed his theory of “immune
surveillance”, where tumor cells are rapidly eliminated
by the immune system on a daily basis. This concept
could not be tested at that time due to lack of appropri-
ate models and in vitro systems. Even immunodeficient
mouse models have failed to provide direct and defini-
tive evidence supporting this theory[7].
The first cancer vaccine in human is attributed to
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resulting in tumor shrinkage. This prompted him to
treat the patients with bacterial extracts. This novel
observation led many to conclude that the immune sys-
tem can recognize tumor-associated antigens. Indirect
or circumstantial evidences are now mounting support-
ing the existence of the cancer immunosurveillance
mechanism in both animals and humans. However, can-
cer also adopts a variety of strategies to evade or sup-
press the immune system. The host-cancer interaction
may or may not lead to tumor eradication. Thus the
concept of “cancer immunosurveillance” is being
replaced by the concept of “cancer immunoediting,”
which emphasizes a dynamic process of interaction
between cancer and the immune system. Operationally,
cancer immunoediting can be divided arbiturilly into
three phases: elimination, equilibrium, and escape, high-
lighting the dynamic interaction between the host
immune system and cancer. In the early phase of tumor
initiation, immune response is effective, resulting in
elimination of cancer. This is followed by a long period
of equilibrium when cancer is not eliminated but it is
kept in check by the immune system and is thus not
clinically detectable. Cancer becomes clinically detect-
able when it has escaped effective anti-tumor immunity.
This concept would predict that the immune system not
only protects the host against the development of pri-
mary cancer, but also sculpts tumor immunogenicities, a
process which has been experimentally confirmed[7].
Initially tumor antigens were broadly classified into
two categories based on their pattern of expression:
tumor-specific antigens (TSA), which are present only
on tumor cells and not on any other cells; and tumor-
associated antigens (TAA), which are present on some
tumor cells and also some normal cells. However, this
classification is imperfect because many antigens that
were thought to be tumor-specific turned out to be
expressed on some normal cells as well. The modern
classification of tumor antigens is based on their mole-
cular structure and source. Several techniques to identify
tumor antigens have been developed, which include ser-
ological identification of antigens by recombinant cDNA
expression cloning (SEREX)[9,10], T-cell epitope cloning
(TEPIC), and bioinformatics[11]. A large array of immu-
nogenic tumor antigens has been identified. Currently,
human tumor antigens are classified into the following
classes: differentiation antigens, overexpression/amplifi-
cation antigens, mutational antigens, cancer testis anti-
gens, oncofetal antigens, and viral antigens[6] (Table 1).
Up to now, over 1,000 human tumor antigens have been
established in a human cancer immunome database
http://ludwig-sun5.unil.ch/CancerImmunomeDB/. This
effort aims to enhance the opportunity for researchers
in the cancer immunology field to design efficacious
immunotherapy strategies through specificically targeted
tumor antigens.
Clinical Evidence for the Role of
Immunosurveillance Against Human Ovarian
Cancer
Intratumoral T cells correlate with clinical outcome
The first evidence of the role of immunosurveillance
against human ovarian cancer was the presence of
tumor-infiltrating lymphocytes (TILs), which correlated
positively and strongly with patient survival[2]. Zhang et
al. (2003) performed immunohistochemical analyses to
assess the distribution of TILs in 186 frozen specimens
from stage III or IV ovarian cancers and conducted clin-
ical outcome analyses. In this study, CD3
+ TILs were
detected within tumor-cell islets in 102 of the 186
tumors (54.8%), whereas CD3
+ TILs were not detected
in 72 of 186 tumors (38.7%); 12 tumors could not be
evaluated (6.5%). They also assessed the number of CD4
+ and CD8
+ T cells in 30 tumors, and the numbers of
CD4
+ and CD8
+ T cells were closely correlated
(R
2 = 0.66, p < 0.001). The immunohistochemical stain-
ing data showed that intratumoral CD4
+ and CD8
+ cells
were either both present or both absent. Patients whose
tumors contained TILs had five-year overall survival
rates of 38%, whereas patients whose tumors lacked
TILs only had five-year overall survival rates of 4.5%.
The five-year progression-free survival rates for patients
w h o s et u m o r sw e r ep r e s e n ta n da b s e n to fT I L sw e r e
31.0% and 8.7% respectively. Thus, overall and progres-
sion-free five-year survival rates were significantly pro-
longed in the patients whose tumors contained TILs
compared to the patients whose tumors did not contain
TILs (p < 0.001 for both comparisons). In a multivariate
analysis, it was shown that the presence or absence of
TILs (p < 0.001) and the extent of residual tumor
(p < 0.001) correlated with overall and progression-free
survival, but patient age (<55 years vs. >55 years), tumor
grade (grade 1 vs. grade 3, grade 2 vs. grade 3), and type
of first-line chemotherapy did not vary with outcomes
[2].
Other studies have confirmed that the intraepithelial
CD3
+ TIL count is a significant prognostic factor in
epithelial ovarian cancer (EOC). Tomšová et al. showed
improved overall survival among 116 EOC patients with
higher versus lower counts of intraepithelial CD3
+ TILs
(> 60 vs. 29 months, respectively, p < 0.0001)[3].
Predictable value of tumor infiltrating regulatory T cells
Sato et al. performed immunohistochemical analyses for
TILs in 117 cases of epithelial ovarian cancer. Patients
with higher frequencies of intraepithelial CD8
+ Tc e l l s
demonstrated improved survival compared to patients
with lower frequencies (55 vs. 26 months; hazard
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tion, the subgroups with high versus low intraepithelial
CD8
+/CD4
+ TIL ratios had median survival rates of 74
months versus 25 months, respectively, with a corre-
sponding hazard ratio of 0.30 (95% C.I., 0.16-0.55; p=
0.0001). These data indicate that CD4
+ TILs influence
the beneficial effects of CD8
+ TIL. The unfavorable
effect of CD4
+ T cells on prognosis is thought to be due
to CD25
+ forkhead box P3 (FOXP3)
+ regulatory T cells
(Treg; suppressor T cells), as indicated by the survival of
patients with high versus low CD8
+/Treg ratios (58 ver-
sus 23 months; hazard ratio = 0.31; 95% C.I., 0.17-0.58;
p = 0.0002)[4]. This observation strongly suggests that
CD4
+CD25
+FOXP3
+ regulatory T cells within the tumor
mass may suppress anti-tumor immunity.
Curiel et al. provided the first direct evidence that
tumor associated CD4
+CD25
+FOXP3
+ Treg cells corre-
late to a poor clinical outcome in epithelial ovarian can-
cer (EOC)[5]. In this study, they revealed a substantial
population of CD4
+CD25
+CD3
+ T cells (10-17% of all T
cells) in malignant ascites from 45 untreated EOC
patients. CD4
+CD25
+CD3
+ T cells were concentrated
much more in malignant ascites than in the peripheral
blood and nonmalignant ascites (0.7-5.0%). Using multi-
color confocal microscopy, the study also found a sub-
stantial accumulation of CD4
+CD25
+CD3
+ T cells
within the tumor mass among 104 tumor specimens
from untreated EOC patients. The percentage of CD4
+CD25
+CD3
+ T cells was higher in stage II-IV disease
than in stage I. In addition, 75% of CD4
+CD25
+CD3
+ T
cells were found in proximity to infiltrating CD8
+ T
cells, which indicated the possibility of inhibition
through physical contact between CD4
+CD25
+CD3
+ T
cells and CD8
+ T cells. Furthermore, they confirmed
that CD4
+CD25
+CD3
+ T cells have characteristics of
Treg cells, which bear the surface phenotype of CD4
+CD25
+CD3
+GITR
+CTLA4
+CCR7
+FOXP3
hi. These cells
also suppressed the proliferation of CD3
+CD25
- T cells,
as well as IFN-g and IL-2 production in vitro.A l s o ,t h e y
found that Tregs preferred to accumulate in the tumor
mass rather than in tumor-draining lymph nodes. More-
over, the CD4
+CD25
+ T cells in tumor-draining lymph
nodes declined from stage I to IV, suggesting they were
preferentially recruited to the tumor mass. They also
showed that tumor Tregs were associated with higher
risk of death and reduced survival time. In multivariate
Table 1 Human Tumor-Associated Antigens*
Antigen category Antigens Tumor type Vaccine Reference
Differentiation Antigens Tyrosinase Melanoma Yes Int J Cancer 1996;67:54[60]
Melan- Mart-1 Melanoma Yes Cancer J Sci Am 1997; 3:37[61]
gp-100 Melanoma Yes Nat Med 1998; 4:321[62]
Overexpression/
Amplification
HER-2/neu Ovarian cancer Breast cancer Yes J Clin Oncol. 2002; 20:2624[13]
Antigens p53 various tumors Yes J Immunol 1998; 160:328[63]
Cancer Immunol Immunother. 2004; 53:633
[64]
Mutational Antigens p53 various tumors Yes J Clin Oncol 2005; 23:5099[65]
Ras various tumors Yes Int J Cancer 2001; 92:441[66]
Cancer Testis Antigens MAGE Melanoma Yes Int J Cancer 1999; 80:219[67]
NY-ESO-1 Ovarian cancer Yes Clin Cancer Res. 2008; 14:2740[31]
LAGE-1 Ovarian cancer Melanoma Bladder
cancer
No Cancer Res. 2003; 63:6076[20]
Glycolipid Antigens MUC-1 Adenocarcinoma Yes J. Clin. Invest. 1997; 100:2783[68]
MUC-16 (CA125) Ovarian cancer Yes Int J Cancer 2002; 98:737[69]
Clin Cancer Res. 2004; 22:3507[70]
Oncofetal Antigens AFP Germ cell tumors No Gynecol. Oncol. 2000; 77:203[71]
CEA Colorectal cancer Yes Ann Surg Oncol 1996; 3:495[72]
PSA Prostate cancer Yes Urology 1999; 53:260[73]
Viral Antigens HPV Cervical cancer Yes Lancet 1996; 347:1523[74]
*This represents only a partial list of tumor antigens for immunotherapy.
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experienced a 25.1-fold risk of death compared to those
with the lowest Treg content (95% C.I., 6.8-92.1). After
controlling for stage of disease and surgical debulking,
tumor Treg cells were a significant predictor for death
and survival in ovarian cancer[5]. Another study showed
that high FoxP3 mRNA expression in tumor samples
from patients with invasive ovarian cancer had poorer
overall survival (27.8 vs. 77.3 months, p = 0.0034) and
progression-free survival (18 vs. 57.5 months; p =
0.0041) when compared with patients with lower FoxP3
mRNA expression.
In Cox multivariate regression analysis, FoxP3 high
expression was an independent prognostic factor for
both progression-free and overall survival (p = 0.004).
These studies strongly suggest that the immune
response against ovarian cancer is a significant and inde-
pendent prognostic factor. It highlights the possibility that
favorable anti-ovarian cancer immune response could
indeed result in improvement of the clinical outcome[12].
Ovarian Cancer Immunotherapy as an Effective
Treatment Modality: The Hypothesis
Ovarian cancer of epithelial origin is an adenocarcinoma
of the epithelial lining of the ovary. Because of the cryp-
tic location of the ovary, ovarian cancer is usually diag-
nosed after regional or distant metastasis. The major
cause of mortality is clinical relapse. Following standard
surgery and chemotherapy, immunotherapy may boost
the memory anti-tumor immune response to eradicate
residual micrometastatic disease and to prevent relapse
when given the consolidation therapy. Immunotherapy
as a potential approach for treatment of ovarian cancer
is based on the following evidence: (1) ovarian cancers
express tumor-associated antigens, e.g. HER2/neu
[13,14], MUC1[15], OA3[16], membrane folate receptor
[17], TAG-72[18], mesothelin[19], NY-ESO-1[20], and
sialyl-Tn[21], which can serve as targets for humoral
and cellular immune responses; (2) the presence of TILs
correlates strongly with survival[2]; (3) ovarian cancers
express peptide/MHC complexes, which can be recog-
nized by CD8
+ T lymphocytes; (4) and most impor-
tantly, the dynamic interaction between host immunity
and cancer indicate that the balance between the two
forces can be tipped to favor the host immunity, with
the ever increasing arsenals of the immunological nat-
ure. Taken together, it has been hypothesized that
immunotherapy could be an innovative and effective
supportive therapy for ovarian cancer.
Clinical Trials of Immunotherapeutic Strategies
Against Ovarian Cancer: the Opportunities
Current immunotherapeutic treatment options for ovar-
ian cancer include but are not limited to therapy with
antibodies (Abs) for example against CA125 and idioty-
pic antibodies, cytokines (such as IFNg,I L - 2 ) ,a c t i v e
immunization with gene transduced whole tumor cells,
peptide-based vaccines, dendritic cell vaccines and heat
shock protein (HSP) vaccines. These modalities are at
different phases of clinical investigation and, currently,
are not the standard of care. Key clinical studies are
summarized in Table 2, some of which we describe in
more detail below. Strengths and limitations of
approaches are listed in Table 3.
Antibody-based vaccines
Antibody-based cancer immunotherapy has now become
a standard practice in the treatment of lymphoma and
other cancers. CA-125, also known as MUC16 is a well-
studied ovarian cancer antigen which was initially iden-
tified by Bast, et al. in 1981[22]. CA-125 is a surface gly-
coprotein antigen, which is elevated in 79% of all
patients with ovarian cancer[23] and in 95% of patients
with stages III and IV ovarian cancer[24].
Oregovomab (Mab B43.13) is a murine monoclonal
antibody that binds to CA-125 with high affinity and
can induce both humoral and cellular immune
responses against ovarian cancer. Ehlen et al. performed
ap i l o tp h a s eI Is t u d yt oe x a m i n et h ei m m u n o l o g i ca n d
clinical effect of oregovomab in pretreated patients with
recurrent ovarian cancer[25]. More than 50% of patients
were successfully induced to generate an anti-CA125
antibody as well as CA125 or oregovomab-specific T
cells. Three of thirteen patients had stabilization of dis-
ease and survival for more than 2 years. In another
phase II trial, the combination of chemotherapy and
oregovomab in 20 patients with recurrent epithelial
ovarian cancer was studied[26]. Fifteen out of the nine-
teen patients (79%) developed humoral responses,
including human anti-mouse antibodies and antibodies
against oregovomab. Two patients (11%) developed anti-
CA125 antibodies, whereas 7 of 18 (39%) patients pro-
duced CA125 specific T cells. In 5 of 8 (63%) patients,
T cell response was specific for autologous tumor, and
in 9 of 18 (50%) patients, the T cell response was direc-
ted against oregovomab. Patients who had a T-cell
immune response showed significantly improved
survival.
In addition, many investigators have attempted to use
an anti-idiotype antibody to increase immunogenicity.
Based on Jerne’s network theory, immunization with a
given antigen will generate specific antibodies against
the antigen (termed Ab1). Ab1 can generate anti-idioty-
pic antibodies against Ab1, termed Ab2. Some of the
anti-idiotypic antibodies (Ab2b)e x p r e s st h ei n t e r n a l
image of the antigen recognized by the Ab1 antibody
and can thus be used as surrogate antigens. Immuniza-
tion with Ab2b could lead to the development of anti-
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Strategies Phase Immune response Clinical response Reference
Antibody-based vaccine
Anti-CA125 (Oregovomab MAb
B43.13)
I/II Increased Ag specific T cells Improved survival [25,26,75,76]
Anti-idiotype Ab (ACA-125) I/II Induced Ab3, Ab1 and ADCC of CA125
+ tumor
cells
Improved survival [28,77]
Anti-HER-2 (trastuzumab,
pertuzumab)
I/II NR* Stable disease for more than 2.5
months
[78,79]
Anti-MUC-1 idiotypic Ab
(HMFG1)
I/II Induced Humoral Immune Responses Prolonged survival [80,81]
Peptide vaccine
HER2/neu I/II Developed humoral and T cell immune
Response
NR* [13,14]
NY-ESO-1 I Induced both humoral and cellular immune
responses
NR* [82,83]
Cytokine vaccine
IL-2 I/II NR* Prolonged survival [84]
IFN-a I/II NR* 20% complete and 8% partial
response
[85-87]
IFN-g I Increased cytotoxity against tumor associated
macrophages
NR* [32,88,89]
Tumor cell vaccine
Whole tumor cells I CD8 T-cell response No clinical response [33]
Tumor cells transfected with GM-
CSF
I NR* Improve survival [34]
Dendritic cell vaccine
DC pulse with autologous tumor
antigen
I DTH NR* [90]
DC pulse with mRNA of FR-a CD4+ and CD8+ T-cell responses NR* [91]
DC/tumour-fusion vaccine Pre-clinical
trial
Elevated serum levels of ANA NR* [92]
DC pulse with peptide Pre-clinical
trial
CTL NR* [43]
HSP vaccine
Gp96 I Increased NK cell activity [unpublished
data]
* Not reported
Table 3 Summary of the Strengths and Limitations of Ovarian Cancer Immunotherapy
Strategies Pros Cons
Antibody-based vaccine Tumor antigen specific. Easy to produce. Weak immunogenicity. Not for all individuals.
Peptide vaccine Safe, stable, and easy to produce and modify. Poor immunogenicity. HLA restriction.
Cytokine vaccine Easy to manufacture and administer. Non-specific immunomodulating only.
Tumor cell vaccine Convenience, contained tumor antigen pool. Potential safety concern. Difficult to produce.
Difficult to standardize.
Dendritic cell vaccine Powerful professional antigen presenting cells. May prime both T
cells and antibody response.
Difficult to manufacture and standardize.
HSP vaccine May contain multiple antigens. Difficult to manufacture and standardize.
Immunomodulation with
Treg blockage
Promising strategy No data on ovarian cancer yet
Difficult to completely eliminate Treg.
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corresponding original antigen identified by Ab1[27].
Abagovomab (formerly ACA-125) is a mouse anti-idio-
type monoclonal antibody whose variable epitope mir-
rors CA-125. In a phase I/IIb study, 119 patients with
advanced ovarian cancer were treated with abagovomab.
A specific anti-anti-idiotypic antibody (Ab3) was
induced in 81 patients (68.1%). Fifty percent of patients
developed a specific anti-CA125 antibody and 26.9% of
patients were found to have antibody-dependent cell-
mediated cytotoxicity of CA125-positive tumor cells.
The median survival rate of all patients was 19.4 months
(range: 0.50-56 months). However, Ab3-positive patients
showed a significantly longer survival rate (median, 23.4
months; p < 0.0001) compared with Ab3-negative
patients (median, 4.9 months)[28]. A second Phase I
trial of abagovomab, consisting of 36 patients with
recurrent ovarian cancer, compared 9 applications
(group L) with 6 applications (group S). Ab3 was
induced in all evaluable patients. A more than twofold
increase of IFN-g-expression CA125-specific CD8
+ T
cells was observed at least once during the immuniza-
t i o ni n9o f1 2( 7 5 % )p a t i e n t so fg r o u pLa n d3o f1 7
(17.6%) of group S (p = 0,006). However, there was no
consistent correlation between the induction of Ab3 and
frequencies of CA125-specific CTL and T helper cells
[29].
HMFG1 is a murine monoclonal antibody with speci-
ficity to MUC1, a cell surface glycoprotein that is
expressed by more than 90% of epithelial ovarian cancer
and other tumors. In a phase I/II study, 52 patients with
epithelial ovarian cancer were treated with yttrium-90-
labelled monoclonal antibody HMFG1 administered
intraperitoneally. After the completion of conventional
surgery and chemotherapy, 21 of the 52 patients had no
evidence of residual disease. These data suggest that the
survival of patients who received the intraperitoneal
antibody was prolonged compared to that of historical
controls[30].
Peptide vaccines
Using peptide as immunogens for immunotherapy has
many advantages, since peptides are well defined and
the risk for sharing with normal cellular proteins can be
minimized. In addition, peptide antigens are easy to
manufacture, stable, and can be modified to increase
their immunogenicity. However, peptide vaccines usually
have poor immunogenicity and need to be administered
w i t ha d j u v a n t ss u c ha sG M - C S F .D i s i sa n dh e rc o l l e a -
gues have performed multiple phase I/II clinical trials
using HER2 derived peptides for the treatment of
patients with HER2 overexpressing tumors. Consistent
HER2-specific T cell response was generated. Moreover,
epitope spreading was seen in some patients. The
magnitude of the T cell response appears to correlate
favorably with the clinical response[13].
NY-ESO-1, another promising cancer-testis antigen, is
expressed by more than 40% of advanced epithelial
ovarian cancers. Diefenbach et al.p e r f o r m e dap h a s eI
study to evaluate the effects of vaccination with the
HLA-A0201-restricted NY-ESO-1b peptide on patients
with high-remission-risk epithelial ovarian cancer, and
found that the NY-ESO-1 peptide-based vaccine was
safe and induced specific T-cell immunity in both NY-
ESO-1 positive and NY-ESO-1 negative patients[31].
Cytokine vaccines
Exogenously supplied cytokines provide immune regula-
tion and maximize the induction, amplification, and/or
effector properties of the desirable immune response in
the microenvironment of the vaccination site. Combina-
tions of cytokines and chemotherapeutic agents have
been tested against ovarian cancer. For example, Schme-
ler et al. from MD Anderson Cancer Center have
recently reported the completion of a phase II study to
evaluate the efficacy and toxicity of carboplatin, granulo-
cyte-macrophage colony-stimulating factor (GM-CSF)
and recombinant interferon gamma 1b (rIFN-g 1b) in
women with recurrent and platinum-sensitive ovarian,
fallopian tube and primary peritoneal cancer[32]. Eligible
patients were treated with subcutaneous GM-CSF and
rIFN-g 1b before and after intravenous carboplatin until
disease progression or unacceptable toxicity. All patients
had measurable disease and a chemotherapy-free inter-
val greater than 6 months. Fifty-nine patients received a
median of 6 cycles of therapy (range, 1 to 13 cycles).
Median age at enrollment was 61 years (range, 35 to 79
years). Median time to progression prior to enrollment
w a s1 1m o n t h s( r a n g e ,6t o5 8m o n t h s ) .O ft h e5 4
patients evaluable for response, 9 (17%) had a complete
response, 21 (39%) had a partial response, and 24 (44%)
exhibited progressive disease. The overall response rate
was 56% (95% CI: 41% to 69%). With a median follow-
up of 6.4 months, median time to progression was 6
months. Myeloid derived cells and platelets increased on
day 9 of each chemotherapy cycle. The most common
adverse effects were bone marrow suppression, carbo-
platin hypersensitivity, and fatigue. Responders reported
improved quality of life. Although it is difficult to evalu-
ate the clinical efficacy in the phase II setting, the safety
profile and encouraging response warrant further study
of this approach.
Tumor cell vaccines
In the absence of known tumor antigens, whole tumor
cell vaccines offer a simple way to prepare the vaccine
which contains a broad tumor antigen repertoire. But
whole tumor cells are poorly immunogenic due to their
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immunogenicity, the whole tumor cell vaccines need to
be associated with a specific adjuvant. In a phase I trial,
Berd et al. modified autologous cancer cells with the
hapten, dinitrophenyl (DNP). Administration of the
DNP-tumor cell vaccine to patients with metastatic mel-
anoma induced inflammation in metastatic sites. Histo-
logically, most of the infiltration of T lymphocytes were
CD8
+ cells[33]. Investigators have tried to modify tumor
cell vaccines by transducing GM-CSF into tumor cells.
Nemunaitis et al. conducted a phase I/II multicenter
trial in patients with early and advanced stage non-
small-cell lung cancer. Vaccines were successfully manu-
factured for 67 patients, and 43 were vaccinated. Survi-
val in patients receiving vaccines secreting higher
amounts of GM-CSF (median survival = 17 months,
95% CI; 6 to 23 months) was significantly longer than in
patients receiving vaccines secreting less GM-CSF (med-
ian survival = 7 months, 95% CI; 4 to 10 months) (p =
0.028)[34].
Dendritic cell vaccines
Dendritic cells (DCs) are major professional antigen-pre-
senting cells which control primary and secondary
immune responses to various exogenous antigens
through antigen cross-presentation and cross-priming of
T cells[35,36]. DCs also play important roles in estab-
lishing anti-tumor immunity and autoimmunity [37-39],
both of which are immune responses to self-antigens
through the breakdown of immune tolerance. Because
DCs have a potential to induce antigen-specific anti-
tumor immunity, several clinical trials of cancer immu-
notherapy using DC vaccines have been performed
[40,41]. Gong et al. used a tumor cell/DC fusion strat-
egy[42]. In this study, human ovarian cancer cells were
fused to human DCs, and they found that the fused
cells were functional in stimulating the proliferation of
autologous T cells, inducing cytolytic T cell activity and
the lysis of autologous tumor cells by a MHC class I-
restricted mechanism[42]. Brossart et al. treated patients
with advanced breast and ovarian cancer with autolo-
gous DCs pulsed with HER-2/neu- or MUC1-derived
peptides. In 5 of 10 (50%) patients, peptide-specific cyto-
toxic T lymphocytes (CTLs) were generated after vacci-
nation. The major CTL response in vivo was induced
with the HER-2/neu-derived E75 and MUC1-derived
M1.2 peptide. The DC vaccinations were well tolerated
with minimal side effects[43].
Heat shock protein vaccines
HSPs are best known as molecular chaperones, which
play vital roles in assisting protein folding[44]. A num-
ber of mammalian HSPs (gp96, HSP90, HSP70, calreti-
culin, HSP110, grp170), when isolated from tumor cells,
have been shown to elicit tumor-specific immunity, and
when isolated from virus-infected cells, have been
demonstrated to elicit virus-specific immunity[45,46].
The immunity in each case is specific to the individual
tumor (or virus-infected cell) that was used as the
source of the HSP preparation. A large number of clini-
cal trials have been carried out to determine if tumor-
derived HSP preparations are able to elicit tumor-speci-
fic immunities. Results from human clinical trials in our
institution and others in melanoma, renal cell cancer,
chronic myelogenous leukemia and other diseases are
consistent with the murine experience [47-50].
The effects of HSPs against a wide spectrum of can-
cers, across species, appear to be related to three key
features: (1) HSPs that are isolated from cancer cells,
although pure and homogenous, are bound to a wide
array of peptides, including antigenic tumor-specific
peptides. Therefore, pure HSPs isolated from a tumor
cell also contain the entire antigenic peptides from this
cell[46]. (2) HSP-peptide complexes can interact with a
conserved receptor molecule CD91 on the surface of
DCs[51]. These complexes are internalized by DCs, and
the peptides that were chaperoned by HSPs are cross-
presented by MHC I molecules of the DCs. These MHC
I-peptide complexes now stimulate naïve CD8
+ Tc e l l s
that mediate the anti-tumor activity. (3) HSP-DC inter-
action also leads to the activation of DCs, resulting in
the production of proinflammatory cytokines and upre-
gulation of co-stimulatory molecules which are neces-
sary for the activation of T cell responses[46].
Our laboratory conducted a pilot study on the roles of
the autologous ovarian cancer-derived gp96-peptide
complex in the treatment of patients with stage III and
IV ovarian cancer in the consolidation setting[52]. We
hypothesized that effective immune intervention at the
time of minimal residual disease is the ideal means to
prevent relapses of this disease. Patients who completed
the standard therapy with no disease progression were
eligible to receive the vaccine. Seven patients (6 with
stage IIIc disease, 1 with stage IIIb cancer) completed
the gp96 injection at 25 μg i.d., weekly for 8 weeks.
Grade II or higher toxicity was not observed. No clinical
evidence of autoimmunity was found. Five out of seven
patients showed increased frequency of IFNg-producing
cells in the peripheral blood against gp96-pulsed autolo-
gous antigen-presenting cells (APCs) that are MHC
class I-dependent. Of interest, 6 out of 7 patients
demonstrated increased NK cell activity, measured by
IFNg ELISPOT against NK cell target K562 cells. This
finding is consistent with our prior study that demon-
strated a significant increase of NK cell activity in
patients with chronic myeloid leukemia (CML) after
vaccination with HSP70, which led us to hypothesize
that HSPs are able to mediate NK-DC cross-talk[49,53].
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feasible, well tolerated and is able to induce favorable
immune responses against ovarian cancer.
What are the Challenges for Ovarian Cancer
Immunotherapy?
Although various immunotherapeutic approaches have
been examined for the treatment of ovarian cancer, it
remains true that no such therapy has entered into the
clinical standard of care. Below we outline several chal-
lenges that need to be overcome.
When patients are diagnosed with cancer, by defini-
tion, the tumor has “escaped” the immune system, hav-
ing passed the phases of “elimination” and
“equilibrium”. Although there is no shortage of ovarian
cancer antigens due to genomic instability and accumu-
lation of mutated genes at this point, the generation of
immune response against these antigens is likely unpro-
ductive in the late stage, due to multiple immune toler-
ance mechanisms such as Treg infiltration in the tumor
bed, general immune suppression from immunosuppres-
sive cytokines by tumor cells, and down-regulation of
MHC class I molecules on the tumor cells. Also, mye-
loid-derived suppressor cells (MDSC) and tumor-asso-
ciated macrophages (TAM) create an
immunosuppressive environment that leads to suppress
T cell responses [54-56]. Thus, multiple immunological
“brakes” need to be lifted to augment productive
immune response. Currently, clinical studies examine
one parameter at a time, which is perhaps too little too
late. Combined immunotherapeutic modalities need to
be seriously considered in order to break the “glass is
half empty” reality of the current immunotherapy land-
scape in the treatment of ovarian cancer.
There are also practical challenges. It is an unclear
and certainly not a trivial question to ask how immu-
notherapy shall be incorporated into conventional ther-
apy. Surgery and chemotherapy are all seriously
immunosuppressive at certain circumstances [57,58],
making them very difficult to combine with immu-
notherapy. Hence, the field is moving toward immuno-
logical intervention of patients after the completion of
conventional therapy. One bold question is whether or
not immunotherapy shall be moved up front, to be fol-
lowed by surgery and chemotherapy. This seemingly
counter-intuitive idea is founded on the premise that
antigen-specific memory cells might well withstand con-
ventional chemotherapy. Better yet, cancer vaccines
should ideally be given to women in the high-risk cate-
gory who have not yet been diagnosed with clinical can-
cer, during the “equilibrium” phase. This last scenario
also depends, in part, on the ability of the medical field
to screen and diagnose ovarian cancer much earlier than
we are currently able to achieve. Lastly, it is worthwhile
to reiterate that combined immunological modalities
m a yb et h eb e s tw a yt om o v ef o r w a r d .T h i sa p p r o a c h
demands the collaboration of investigators and the crea-
tivity of regulatory agencies such as the FDA for
approval of novel combinations of various approaches in
situations where none of these approaches alone has
been shown to be effective yet.
Conclusion and Perspectives
In light of highly promising advancements in the science
of immunotherapy against ovarian cancer coupled with
encouraging results from numerous clinical trials, we
suggest that bold steps need to be taken to further this
area of research. First, a more permissive regulatory cli-
mate is needed to allow investigators to combine various
non-proven modalities in hopes of finding an effective
combination. Second, we should focus on finding bio-
markers for early diagnosis or prognosis and individual
treatment. Serum proteomics applications could identify
blood-based biomarkers for early diagnosis and prog-
nosis[59], and tissue proteomics could help to define
targets for individualized treatment. Third, we should
debate the merits to move immune intervention ahead
of conventional therapy or even to high-risk patients in
the prophylactic setting. Finally, resources and funding
must be given to support the important translational
groundwork by cancer immunologists and physician
scientists. Without these critical steps, we might face
the same uncertainty about therapy against this dreadful
disease for years to come.
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